CHORIORETINAL ATROPHY

This adverse event was reported 207 times

These drugs are most commonly taken by patients reporting CHORIORETINAL ATROPHY:

# Drug Count
0 MELPHALAN HYDROCHLORIDE 67
1 TOPOTECAN 23
2 RANIBIZUMAB 19
3 CARBOPLATIN 16
4 BEVACIZUMAB 15
5 VERTEPORFIN FOR INJECTION 14
6 PREDNISOLONE 12
7 PREDNISOLONE ORAL 12
8 PREDNISOLONE ORAL SOLUTION 12
9 PREDNISONE 9
See all common drugs associated with CHORIORETINAL ATROPHY

CHORIORETINAL ATROPHY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 VORETIGENE NEPARVOVEC-RZYL 8 0.0526
1 VERTEPORFIN FOR INJECTION 14 0.0095
2 FOSAMPRENAVIR CALCIUM 1 0.0076
3 NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND DEXAMETHASONE 5 0.0046
4 TOPOTECAN 23 0.0038
5 PROPARACAINE HYDROCHLORIDE 2 0.0037
6 FLUORESCEIN 2 0.0032
7 MELPHALAN HYDROCHLORIDE 67 0.0026
8 CHLOROQUINE PHOSPHATE 1 0.0015
9 TOPOTECAN HYDROCHLORIDE 3 0.0012
See all drugs enriched for association with CHORIORETINAL ATROPHY

CHORIORETINAL ATROPHY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Photoenhancer [EPC] 14 0.0036
1 Diagnostic Dye [EPC] 2 0.0031
2 Anticholinergic [EPC] 8 0.0005
3 Guanylate Cyclase-C Agonist [EPC] 1 0.0005
4 CCR5 Co-receptor Antagonist [EPC] 1 0.0004
5 Topoisomerase Inhibitor [EPC] 23 0.0003
6 Antiseptic [EPC] 1 0.0002
7 alpha-1 Adrenergic Agonist [EPC] 1 0.0002
8 Vascular Endothelial Growth Factor Inhibitor [EPC] 37 0.0002
9 Sulfone [EPC] 2 0.0002
See all drug classes enriched for association with CHORIORETINAL ATROPHY